Making vaccines "on demand" : A potential solution for emerging pathogens and biodefense?

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1877-1884

  De Groot, Anne S ^a,b   Einck, Leo ^a   Moise, Leonard ^a   Chambers, Michael ^c   Ballantyne, John ^c   Malone, Robert W ^d   Ardito, Matthew ^a   Martin, William ^a  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c Aldevron LLC   (United States)

^d WCCT Global Inc   (United States)

Author keywords

Biothreat; Coronavirus; Emerging infectious disease; H5N1; H7N9; Immunoinformatics; Medical countermeasure; SARS; Vaccine

Indexed keywords

DNA VACCINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; VACCINE;

2009 H1N1 INFLUENZA; ACTIVE IMMUNIZATION; BIOLOGICAL WARFARE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EMERGENCY TREATMENT; EPITOPE MAPPING; HUMAN; IMMUNOGENICITY; LIFE THREAT; NONHUMAN; REVIEW; SCALE UP; VACCINE PRODUCTION;

BIOTHREAT; CORONAVIRUS; EMERGING INFECTIOUS DISEASE; H5N1; H7N9; IMMUNOINFORMATICS; MEDICAL COUNTERMEASURE; SARS; VACCINE;

BIOLOGICAL WARFARE AGENTS; CIVIL DEFENSE; COMMUNICABLE DISEASES, EMERGING; HUMANS; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; VACCINES;

EID: 84884651094     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25611     Document Type: Review

References (69)

1. Graham B, Talent J. World at Risk. 2008 Dec 3. Retrieved from http://www.preventwmd.gov/static/docs/report/worldatrisk-full.pdf
2. Graham B, Talent J. Prevention of WMD Proliferation and Terrorism Report Card. 2010. Retrieved from http://www.preventwmd.gov/static/docs/report-card.pdf
3. Government Accounting Agency. Report GAO-11-318SP: Homeland security/Law enforcement: Strategic oversight mechanisms could help integrate fragmented interagency efforts to defend against biological threats. 2011 Mar 1. Retrieved from http://www.gao.gov/modules/ereport/handler.php?m=1&p=1&path=/ ereport/GAO-11-318SP/data-center/Homeland-security-Law-enforcement/ Strategic-oversight-mechanisms-could-help-integrate-fragmented-interagency- efforts-to-defend-against-biological-threats
4. Franco C, Sell TK. Federal agency biodefense funding, FY2012-FY2013. Biosecur Bioterror 2012; 10:162-81; PMID:22691277; http://dx.doi.org/10.1089/ bsp.2012.0025
5. Department of Health and Human Services. HHS creates new centers to develop, manufacture medical countermeasures. 2012. Retrieved from http://www.hhs.gov/news/press/2012pres/06/20120618a.html
6. GISAID. EpiFlu Database. 2008-2013. Retrieved from http://platform. gisaid.org/epi3/frontend#36c986
7. De Groot AS, Ardito M, Moise L, Gustafson EA, Spero D, Tejada G, et al. Immunogenic consensus sequence T helper epitopes for a pan-Burkholderia biodefense vaccine. Immunome Res 2011; 7:7; PMID:22130150
8. Simmons CP, Hussell T, Sparer T, Walzl G, Openshaw P, Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol 2001; 166:1106-13; PMID:11145691
9. Franke ED, Sette A, Sacci J Jr., Southwood S, Corradin G, Hoffman SL. A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture. Infect Immun 2000; 68:3403-11; PMID:10816491; http://dx.doi.org/10.1128/IAI.68.6.3403-3411.2000
10. Schadeck EB, Partidos CD, Fooks AR, Obeid OE, Wilkinson GW, Stephenson JR, et al. CTL epitopes identified with a defective recombinant adenovirus expressing measles virus nucleoprotein and evaluation of their protective capacity in mice. Virus Res 1999; 65:75-86; PMID:10564754; http://dx.doi.org/10. 1016/S0168-1702(99)00103-3
11. Rosenthal KS, Mao H, Horne WI, Wright C, Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 1999; 17:535-42; PMID:10075159; http://dx.doi.org/10.1016/ S0264-410X(98)00231-X
12. Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, Nussenzweig RS, et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 1998; 72:6907-10; PMID:9658144
13. Hislop AD, Good MF, Mateo L, Gardner J, Gatei MH, Daniel RC, et al. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nat Med 1998; 4:1193-6; PMID:9771756; http://dx.doi.org/10.1038/2690
14. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75:4040-7; PMID:11287553; http://dx.doi.org/10.1128/JVI.75.9.4040-4047.2001
15. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009; 27:5740-7; PMID:19660593; http://dx.doi.org/10.1016/j.vaccine.2009.07.040
16. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:20365-70; PMID:19918065; http://dx.doi.org/10.1073/pnas.0911580106
17. Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, et al. Coupling sensitive in vitro and in silico techniques to assess crossreactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011; 29:3299-309; PMID:21349362; http://dx.doi.org/10.1016/j.vaccine.2011.02.019
18. De Groot AS, Ardito M, Terry F, Levitz L, Ross TM, Moise L, et al. Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design. Hum Vaccin Immunother 2013; 9:950-6; PMID:23807079; http://dx.doi.org/10.4161/hv.24939
19. Gilbert SC. T-cell-inducing vaccines - what's the future. Immunology 2012; 135:19-26; PMID:22044118; http://dx.doi.org/10.1111/j.1365-2567.2011. 03517.x
20. Hastie KM, Kimberlin CR, Zandonatti MA, MacRae IJ, Saphire EO. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 2011; 108:2396-401; PMID:21262835; http://dx.doi.org/10.1073/pnas.1016404108
21. Cohen T, Moise L, Martin W, DeGroot AS. Immunoinformatics: The next step in vaccine design. In: Sintchenko V, ed. Infectious Disease Informatics. New York: Springer, 2010:223-244.
22. De Groot AS, Martin W. From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Found Symp 2003; 254:57-72, discussion 72-6, 98-101, 250-2; PMID:14712932; http://dx.doi.org/10.1002/0470090766.ch5
23. De Groot AS. How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past. Vaccine 2003; 21:4095-104; PMID:14505885; http://dx.doi.org/10.1016/S0264-410X(03)00489-4
24. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009; 27:5740-7; PMID:19660593; http://dx.doi.org/10.1016/j.vaccine.2009.07.040
25. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, et al. VennVax, a DNA-prime, peptideboost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501-11; PMID:21055490; http://dx.doi.org/10.1016/j.vaccine. 2010.10.064
26. De Groot AS, Saint-Aubin CS, Bosma A, Sbai H, Rayner J, Martin W. Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome. Emerg Infect Dis 2001; 7:706-13; PMID:11585536
27. De Groot AS, Martin W, Moise L, Guirakhoo F, Monath T. Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine 2007; 25:8077-84; PMID:17942198; http://dx.doi.org/10.1016/j.vaccine.2007.09.026
28. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011; 29:2085-91; PMID:21236233; http://dx.doi.org/10.1016/j.vaccine. 2010.12.130
29. De Groot AS, Ardito MA, Terry F, Levitz L, Ross TM, Moise L, et al. Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design. Hum Vaccin Immunother 2013; 9; PMID:23807079; http://dx.doi.org/10.4161/hv.24939
30. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, Bui HH, et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 2006; 24:817-9; PMID:16767078; http://dx.doi.org/10.1038/nbt1215
31. Moise L, De Groot AS. Putting immunoinformatics to the test. Nat Biotechnol 2006; 24:791-2; PMID:16841062; http://dx.doi.org/10.1038/nbt0706-791
32. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005; 174:7676-83; PMID:15944268
33. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-12; PMID:10602880; http://dx.doi.org/10.1007/s002510050594
34. Schirmbeck R, Fissolo N, Chaplin P, Reimann J. Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides. J Immunol 2003; 171:1240-6; PMID:12874211
35. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 2012; 11:189-209; PMID:22309668; http://dx.doi.org/10.1586/ erv.11.188
36. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009; 333:369-93; PMID:19768415; http://dx.doi.org/10.1007/978-3-540-92165-3-18
37. Ramirez LA, Arango T, Boyer J. Therapeutic and prophylactic DNA vaccines for HIV-1. Expert Opin Biol Ther 2013; 13:563-73; PMID:23477730; http://dx.doi.org/10.1517/14712598.2013.758709
38. Dhir V, Fort M, Mahmood A, Higbee R, Warren W, Narayanan P, et al. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J Immunotoxicol 2012; 9:34-42; PMID:22074378; http://dx.doi.org/10.3109/1547691X.2011.613419
39. Perdue ML, Bright RA. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. [Review]. Vaccine 2011; 29(Suppl 1):A48-50; PMID:21684430; http://dx.doi.org/10.1016/j.vaccine.2011.02.080
40. Sonpavde G, Kantoff PW. Immunotherapy for castration-resistant prostate cancer. [Review]. Urol Clin North Am 2012; 39:465-81; PMID:23084524; http://dx.doi.org/10.1016/j.ucl.2012.07.004
41. Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother 2012; 8:534-9; PMID:22832254; http://dx.doi.org/10.4161/hv.19795
42. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127
43. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID:23390376
44. Gilbert SC. T-cell-inducing vaccines - what's the future. Immunology 2012; 135:19-26; PMID:22044118; http://dx.doi.org/10.1111/j.1365-2567.2011. 03517.x
45. Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.PLoS One 2013; 8:e62778; PMID:23658773; http://dx.doi.org/10.1371/journal.pone.0062778
46. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012; 55:19-25; PMID:22441650; http://dx.doi.org/10.1093/cid/cis327
47. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 2008; 82:1448-57; PMID:18032491; http://dx.doi.org/10. 1128/JVI.01409-07
48. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 2003; 302:602; PMID:14576423; http://dx.doi.org/10.1126/science.1092329
49. Pederson T. The immunome. Mol Immunol 1999; 36:1127-8; PMID:10698314; http://dx.doi.org/10.1016/S0161-5890(99)00125-X
50. De Groot AS, Martin W. From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Found Symp 2003; 254:57-72, discussion 72-6, 98-101, 250-2; PMID:14712932; http://dx.doi.org/10.1002/0470090766.ch5
51. Doytchinova IA, Taylor P, Flower DR. Proteomics in Vaccinology and Immunobiology: An Informatics Perspective of the Immunone. J Biomed Biotechnol 2003; 2003:267-90; PMID:14688414; http://dx.doi.org/10.1155/S1110724303209232
52. De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, Kutzler M, et al. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005; 23:2121-31; PMID:15755582; http://dx.doi.org/10.1016/j.vaccine.2005.01.059
53. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, et al. HIV vaccine development by computer assisted design: the GAIA vaccine.Vaccine 2005; 23:2136-48; PMID:15755584; http://dx.doi.org/10.1016/j.vaccine.2005.01.097
54. Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine 2005; 24:4461-70; http://dx.doi.org/10.1016/j. vaccine.2005.08.010.
55. De Groot AS, Ardito M, Moise L, Gustafson EA, Spero D, Tejada G, et al. Immunogenic consensus sequence T helper epitopes for a pan-Burkholderia biodefense vaccine. Immunome Res 2011; 7:7; http://immunome-research.net/; PMID:22130150.
56. Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, et al. Coupling sensitive in vitro and in silico techniques to assess crossreactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011; 29:3299-309; PMID:21349362; http://dx.doi.org/10.1016/j.vaccine.2011.02.019
57. Levitz L, Koita OA, Sangare K, Ardito MT, Boyle CM, Rozehnal J, et al. Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine 2012; 30:7547-60; PMID:23102976; http://dx.doi.org/10.1016/j.vaccine.2012.10.042
58. De Groot AS, Levitz L, Ardito MT, Skowron G, Mayer KH, Buus S, et al. Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. Hum Vaccin Immunother 2012; 8:987-1000; http://tinyurl.com/GAIA-HLA-A3; PMID:22777092; http://dx.doi.org/10.4161/hv.20528.
59. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, et al. VennVax, a DNA-prime, peptideboost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501-11; PMID:21055490; http://dx.doi.org/10.1016/j.vaccine. 2010.10.064
60. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. HelicoVax: Epitope-based therapeutic H. pylori vaccination in a mouse model of gastric cancer. Vaccine 2011; 29:2085-91; PMID:21236233; http://dx.doi.org/10.1016/j. vaccine.2010.12.130
61. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, et al. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013; 9; PMID:23584251; http://dx.doi.org/10. 4161/hv.24615
62. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry FA, Leng Q, Abdel Hady KM, et al. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013; 9: In press; PMID:23584251; http://dx.doi.org/10.4161/hv.24615.
63. Elfaki ME, Khalil EA, De Groot AS, Musa AM, Gutierrez A, Younis BM, et al. Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother 2012; 8:1769-74; PMID:22922767; http://dx.doi.org/10.4161/hv.21881
64. Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis 2011; 52(Suppl 3):s253-8; PMID:21217172; http://dx.doi.org/10.1093/cid/ciq116
65. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med 2005; 11(Suppl):S25-32; PMID:15812486; http://dx.doi.org/10.1038/nm1212
66. Chen L, Li B, Yang WC, He JL, Li NY, Hu J, et al. A dominant CD4(+) T-cell response to Helicobacter pylori reduces risk for gastric disease in humans. Gastroenterology 2013; 144:591-600; PMID:23232294; http://dx.doi.org/10. 1053/j.gastro.2012.12.002
67. Kaabinejadian S, Piazza PA, McMurtrey CP, Vernon SR, Cate SJ, Bardet W, et al. Identification of Class I HLA T Cell Control Epitopes for West Nile Virus. PLoS One 2013; 8:e66298; PMID:23762485; http://dx.doi.org/10.1371/ journal.pone.0066298
68. Silva EB, Dow SW. Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol 2013; 3:10; PMID:23508691; http://dx.doi.org/10.3389/fcimb.2013.00010
69. Eneslätt K, Normark M, Björk R, Rietz C, Zingmark C, Wolfraim LA, et al. Signatures of T cells as correlates of immunity to Francisella tularensis. PLoS One 2012; 7:e32367; PMID:22412866; http://dx.doi.org/10.1371/ journal.pone.0032367